首页 > 最新文献

Acta Psychiatrica Scandinavica最新文献

英文 中文
Antidepressant-associated diagnostic change from major depressive to bipolar disorder 从重度抑郁症到双相情感障碍的抗抑郁相关诊断变化。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-24 DOI: 10.1111/acps.13721
Leonardo Tondo, Alessandro Miola, Marco Pinna, Martina Contu, Ross J. Baldessarini

Background

Anticipating diagnostic change from major depressive (MDD) to bipolar disorder (BD) can support better prognosis and treatment, especially of depression but is challenging and reported research results are inconsistent. We therefore assessed clinical characteristics associated with diagnostic change from MDD to BD with antidepressant treatments.

Methods

We compared characteristics of 3212 initially MDD patients who became (hypo)manic during antidepressant treatment to those with stable MDD diagnoses as well as with cases of stable, spontaneous BD, using standard bivariate and multivariate statistics.

Results

Among MDD patients, 6.69% [CI: 5.85–7.61] changed to BD, mostly type II (BD2, 76.7%). BD-converters had higher rates of familial mood disorders (74.1% vs. 57.1%) or BD (33.7% vs. 21.0%) and 2.8-years younger onset than stable MDD patients. They also had more prior depressive recurrences/year, years-of-illness, mood-stabilizer treatment, divorces, fewer children, more suicide attempts and drug-abuse, and higher intake cyclothymia, YMRS and MDQ scores. Predictors independently associated with diagnostic conversion were: more familial BD, depressions/year, unemployment, cyclothymic temperament, suicidal ideation or acts, and fewer children. BD-converters vs. spontaneous BD cases had significantly more suicide attempts, BD2 diagnoses, and affected relatives. Converting to vs. spontaneous BD1 was associated with more ADHD, more suicidal ideation or behavior, MDI course, and younger onset; converting to vs. spontaneous BD2 had more episodes/year, unemployment, ADHD, substance abuse, suicidal ideation or attempts, and more relatives with BD.

Conclusions

Few (6.69%) initially MDD subjects converted to BD, most (76.7%) to BD2. Independent predictive associations with diagnostic change included: familial BD, more depressions/year, unemployment, cyclothymic temperament, suicidal behavior and fewer children. Notably, several characteristics were stronger among those changing to BD during antidepressant treatment vs. others with spontaneous BD.

背景:预测从重度抑郁(MDD)到双相情感障碍(BD)的诊断变化有助于更好地预后和治疗,尤其是抑郁症的治疗,但这具有挑战性,而且报告的研究结果也不一致。因此,我们评估了与抗抑郁治疗后从重度抑郁症诊断为双相情感障碍相关的临床特征:我们采用标准的双变量和多变量统计方法,比较了 3212 例最初诊断为 MDD 但在抗抑郁治疗期间转为(低)躁狂的患者与诊断为 MDD 但病情稳定的患者以及病情稳定、自发转为 BD 的病例的特征:在 MDD 患者中,有 6.69% [CI:5.85-7.61] 转为 BD,其中大部分为 II 型(BD2,76.7%)。与稳定型 MDD 患者相比,BD 转换者的家族性情绪障碍(74.1% 对 57.1%)或 BD(33.7% 对 21.0%)发生率更高,发病年龄更小 2.8 岁。他们的抑郁复发次数/年、患病年数、情绪稳定剂治疗次数、离婚次数、子女人数、自杀未遂次数和药物滥用次数也更多,而且摄入的环状嗜铬细胞瘤、YMRS和MDQ评分也更高。与诊断转换独立相关的预测因素有:更多的家族性 BD、抑郁/年、失业、周期性气质、自杀意念或行为以及子女较少。与自发性 BD 病例相比,BD 转换者的自杀企图、BD2 诊断和受影响亲属的人数明显更多。转为BD1与自发BD1的患者有更多的ADHD、更多的自杀意念或行为、MDI病程以及更年轻的发病年龄;转为BD2与自发BD2的患者有更多的发作/年、失业、ADHD、药物滥用、自杀意念或企图以及更多的亲属患有BD:很少(6.69%)最初为 MDD 的受试者转为 BD,大多数(76.7%)转为 BD2。与诊断改变相关的独立预测因素包括:家族性 BD、每年抑郁次数较多、失业、周期性气质、自杀行为和子女较少。值得注意的是,与其他自发性 BD 患者相比,在抗抑郁治疗期间转为 BD 患者的几个特征更为明显。
{"title":"Antidepressant-associated diagnostic change from major depressive to bipolar disorder","authors":"Leonardo Tondo,&nbsp;Alessandro Miola,&nbsp;Marco Pinna,&nbsp;Martina Contu,&nbsp;Ross J. Baldessarini","doi":"10.1111/acps.13721","DOIUrl":"10.1111/acps.13721","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Anticipating diagnostic change from major depressive (MDD) to bipolar disorder (BD) can support better prognosis and treatment, especially of depression but is challenging and reported research results are inconsistent. We therefore assessed clinical characteristics associated with diagnostic change from MDD to BD with antidepressant treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We compared characteristics of 3212 initially MDD patients who became (hypo)manic during antidepressant treatment to those with stable MDD diagnoses as well as with cases of stable, spontaneous BD, using standard bivariate and multivariate statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among MDD patients, 6.69% [CI: 5.85–7.61] changed to BD, mostly type II (BD2, 76.7%). BD-converters had higher rates of familial mood disorders (74.1% vs. 57.1%) or BD (33.7% vs. 21.0%) and 2.8-years younger onset than stable MDD patients. They also had more prior depressive recurrences/year, years-of-illness, mood-stabilizer treatment, divorces, fewer children, more suicide attempts and drug-abuse, and higher intake cyclothymia, YMRS and MDQ scores. Predictors independently associated with diagnostic conversion were: more familial BD, depressions/year, unemployment, cyclothymic temperament, suicidal ideation or acts, and fewer children. BD-converters vs. spontaneous BD cases had significantly more suicide attempts, BD2 diagnoses, and affected relatives. Converting to vs. spontaneous BD1 was associated with more ADHD, more suicidal ideation or behavior, MDI course, and younger onset; converting to vs. spontaneous BD2 had more episodes/year, unemployment, ADHD, substance abuse, suicidal ideation or attempts, and more relatives with BD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Few (6.69%) initially MDD subjects converted to BD, most (76.7%) to BD2. Independent predictive associations with diagnostic change included: familial BD, more depressions/year, unemployment, cyclothymic temperament, suicidal behavior and fewer children. Notably, several characteristics were stronger among those changing to BD during antidepressant treatment vs. others with spontaneous BD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 3","pages":"126-137"},"PeriodicalIF":5.3,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141453794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep-wake variations of electrodermal activity in bipolar disorder. 双相情感障碍患者皮肤电活动的睡眠-觉醒变化。
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-18 DOI: 10.1111/acps.13718
Clàudia Valenzuela-Pascual, Ariadna Mas, Roger Borràs, Gerard Anmella, Miriam Sanabra, Meritxell González-Campos, Marc Valentí, Isabella Pacchiarotti, Antoni Benabarre, Iria Grande, Michele De Prisco, Vincenzo Oliva, Anna Bastidas, Isabel Agasi, Allan H Young, Marina Garriga, Andrea Murru, Filippo Corponi, Bryan M Li, Peter de Looff, Eduard Vieta, Diego Hidalgo-Mazzei

Background: Affective states influence the sympathetic nervous system, inducing variations in electrodermal activity (EDA), however, EDA association with bipolar disorder (BD) remains uncertain in real-world settings due to confounders like physical activity and temperature. We analysed EDA separately during sleep and wakefulness due to varying confounders and potential differences in mood state discrimination capacities.

Methods: We monitored EDA from 102 participants with BD including 35 manic, 29 depressive, 38 euthymic patients, and 38 healthy controls (HC), for 48 h. Fifteen EDA features were inferred by mixed-effect models for repeated measures considering sleep state, group and covariates.

Results: Thirteen EDA feature models were significantly influenced by sleep state, notably including phasic peaks (p < 0.001). During wakefulness, phasic peaks showed different values for mania (M [SD] = 6.49 [5.74, 7.23]), euthymia (5.89 [4.83, 6.94]), HC (3.04 [1.65, 4.42]), and depression (3.00 [2.07, 3.92]). Four phasic features during wakefulness better discriminated between HC and mania or euthymia, and between depression and euthymia or mania, compared to sleep. Mixed symptoms, average skin temperature, and anticholinergic medication affected the models, while sex and age did not.

Conclusion: EDA measured from awake recordings better distinguished between BD states than sleep recordings, when controlled by confounders.

背景:情绪状态会影响交感神经系统,诱发皮电活动(EDA)的变化,然而,在现实世界中,由于身体活动和温度等混杂因素,EDA与双相情感障碍(BD)的关系仍不确定。由于混杂因素的不同以及情绪状态辨别能力的潜在差异,我们分别分析了睡眠和清醒时的EDA:我们对102名BD患者(包括35名躁狂症患者、29名抑郁症患者、38名优郁患者和38名健康对照组(HC))进行了48小时的EDA监测:结果:13 个 EDA 特征模型受到睡眠状态的显著影响,特别是包括阶段性峰值(p 结论:从清醒记录中测量的 EDA 更好地反映了睡眠状态:在控制混杂因素的情况下,从清醒记录中测得的 EDA 比睡眠记录更能区分 BD 状态。
{"title":"Sleep-wake variations of electrodermal activity in bipolar disorder.","authors":"Clàudia Valenzuela-Pascual, Ariadna Mas, Roger Borràs, Gerard Anmella, Miriam Sanabra, Meritxell González-Campos, Marc Valentí, Isabella Pacchiarotti, Antoni Benabarre, Iria Grande, Michele De Prisco, Vincenzo Oliva, Anna Bastidas, Isabel Agasi, Allan H Young, Marina Garriga, Andrea Murru, Filippo Corponi, Bryan M Li, Peter de Looff, Eduard Vieta, Diego Hidalgo-Mazzei","doi":"10.1111/acps.13718","DOIUrl":"https://doi.org/10.1111/acps.13718","url":null,"abstract":"<p><strong>Background: </strong>Affective states influence the sympathetic nervous system, inducing variations in electrodermal activity (EDA), however, EDA association with bipolar disorder (BD) remains uncertain in real-world settings due to confounders like physical activity and temperature. We analysed EDA separately during sleep and wakefulness due to varying confounders and potential differences in mood state discrimination capacities.</p><p><strong>Methods: </strong>We monitored EDA from 102 participants with BD including 35 manic, 29 depressive, 38 euthymic patients, and 38 healthy controls (HC), for 48 h. Fifteen EDA features were inferred by mixed-effect models for repeated measures considering sleep state, group and covariates.</p><p><strong>Results: </strong>Thirteen EDA feature models were significantly influenced by sleep state, notably including phasic peaks (p < 0.001). During wakefulness, phasic peaks showed different values for mania (M [SD] = 6.49 [5.74, 7.23]), euthymia (5.89 [4.83, 6.94]), HC (3.04 [1.65, 4.42]), and depression (3.00 [2.07, 3.92]). Four phasic features during wakefulness better discriminated between HC and mania or euthymia, and between depression and euthymia or mania, compared to sleep. Mixed symptoms, average skin temperature, and anticholinergic medication affected the models, while sex and age did not.</p><p><strong>Conclusion: </strong>EDA measured from awake recordings better distinguished between BD states than sleep recordings, when controlled by confounders.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141416744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why does problem gambling in psychotic disorders pose such a challenge for comprehension? 为什么精神病患者的赌博问题会给理解工作带来如此大的挑战?
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-17 DOI: 10.1111/acps.13720
Thalles Rodrigues Alves Leite, Tainá Conrado Ferreira, Lucas Lima Menezes Albuquerque, Fábio Gomes de Matos e Souza, Luísa Weber Bisol
{"title":"Why does problem gambling in psychotic disorders pose such a challenge for comprehension?","authors":"Thalles Rodrigues Alves Leite,&nbsp;Tainá Conrado Ferreira,&nbsp;Lucas Lima Menezes Albuquerque,&nbsp;Fábio Gomes de Matos e Souza,&nbsp;Luísa Weber Bisol","doi":"10.1111/acps.13720","DOIUrl":"10.1111/acps.13720","url":null,"abstract":"","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 3","pages":"182-183"},"PeriodicalIF":5.3,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141329773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge graphs in psychiatric research: Potential applications and future perspectives. 精神病学研究中的知识图谱:潜在应用和未来展望。
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-17 DOI: 10.1111/acps.13717
Sebastian Freidel, Emanuel Schwarz

Background: Knowledge graphs (KGs) remain an underutilized tool in the field of psychiatric research. In the broader biomedical field KGs are already a significant tool mainly used as knowledge database or for novel relation detection between biomedical entities. This review aims to outline how KGs would further research in the field of psychiatry in the age of Artificial Intelligence (AI) and Large Language Models (LLMs).

Methods: We conducted a thorough literature review across a spectrum of scientific fields ranging from computer science and knowledge engineering to bioinformatics. The literature reviewed was taken from PubMed, Semantic Scholar and Google Scholar searches including terms such as "Psychiatric Knowledge Graphs", "Biomedical Knowledge Graphs", "Knowledge Graph Machine Learning Applications", "Knowledge Graph Applications for Biomedical Sciences". The resulting publications were then assessed and accumulated in this review regarding their possible relevance to future psychiatric applications.

Results: A multitude of papers and applications of KGs in associated research fields that are yet to be utilized in psychiatric research was found and outlined in this review. We create a thorough recommendation for other computational researchers regarding use-cases of these KG applications in psychiatry.

Conclusion: This review illustrates use-cases of KG-based research applications in biomedicine and beyond that may aid in elucidating the complex biology of psychiatric illness and open new routes for developing innovative interventions. We conclude that there is a wealth of opportunities for KG utilization in psychiatric research across a variety of application areas including biomarker discovery, patient stratification and personalized medicine approaches.

背景:在精神病学研究领域,知识图谱(KGs)仍然是一种未得到充分利用的工具。在更广泛的生物医学领域,知识图谱已经是一种重要工具,主要用作知识数据库或生物医学实体之间新关系的检测。本综述旨在概述在人工智能(AI)和大型语言模型(LLM)时代,KGs 将如何促进精神病学领域的研究:我们对从计算机科学、知识工程到生物信息学等多个科学领域进行了全面的文献综述。所查阅的文献来自 PubMed、Semantic Scholar 和 Google Scholar 搜索,包括 "精神病学知识图谱"、"生物医学知识图谱"、"知识图谱机器学习应用"、"生物医学知识图谱应用 "等术语。本综述对这些出版物进行了评估,并就其与未来精神病学应用的可能相关性进行了汇总:结果:在本综述中,我们发现了大量相关研究领域的论文和知识图谱应用,但这些论文和应用尚未用于精神病学研究。我们就这些 KG 在精神病学中的应用案例向其他计算研究人员提出了详尽的建议:本综述阐述了基于 KG 的研究应用在生物医学及其他领域的用例,这些应用可能有助于阐明精神疾病的复杂生物学特性,并为开发创新性干预措施开辟新的途径。我们得出的结论是,KG 在精神病学研究中的应用机会很多,涉及生物标记物发现、患者分层和个性化医疗方法等多个应用领域。
{"title":"Knowledge graphs in psychiatric research: Potential applications and future perspectives.","authors":"Sebastian Freidel, Emanuel Schwarz","doi":"10.1111/acps.13717","DOIUrl":"https://doi.org/10.1111/acps.13717","url":null,"abstract":"<p><strong>Background: </strong>Knowledge graphs (KGs) remain an underutilized tool in the field of psychiatric research. In the broader biomedical field KGs are already a significant tool mainly used as knowledge database or for novel relation detection between biomedical entities. This review aims to outline how KGs would further research in the field of psychiatry in the age of Artificial Intelligence (AI) and Large Language Models (LLMs).</p><p><strong>Methods: </strong>We conducted a thorough literature review across a spectrum of scientific fields ranging from computer science and knowledge engineering to bioinformatics. The literature reviewed was taken from PubMed, Semantic Scholar and Google Scholar searches including terms such as \"Psychiatric Knowledge Graphs\", \"Biomedical Knowledge Graphs\", \"Knowledge Graph Machine Learning Applications\", \"Knowledge Graph Applications for Biomedical Sciences\". The resulting publications were then assessed and accumulated in this review regarding their possible relevance to future psychiatric applications.</p><p><strong>Results: </strong>A multitude of papers and applications of KGs in associated research fields that are yet to be utilized in psychiatric research was found and outlined in this review. We create a thorough recommendation for other computational researchers regarding use-cases of these KG applications in psychiatry.</p><p><strong>Conclusion: </strong>This review illustrates use-cases of KG-based research applications in biomedicine and beyond that may aid in elucidating the complex biology of psychiatric illness and open new routes for developing innovative interventions. We conclude that there is a wealth of opportunities for KG utilization in psychiatric research across a variety of application areas including biomarker discovery, patient stratification and personalized medicine approaches.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141416743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-pandemic trends in psychotropic medication use in Danish children, adolescents, and young adults 大流行后丹麦儿童、青少年和年轻成年人使用精神药物的趋势。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-16 DOI: 10.1111/acps.13719
Helene Kildegaard, Rikke Wesselhoeft, Lars Christian Lund, Mette Bliddal
<p>Mental health among children, adolescents, and young adults deteriorated during the Covid-19 pandemic, leading to concurrent significant rises in utilization of psychotropics.<span><sup>1, 2</sup></span> This escalation in psychotropic medication use raised concerns for potential long-term effects beyond the immediate aftermaths of the pandemic. We aimed to assess rates of incident psychotropic medication use in the post-pandemic period compared with pre-pandemic trends in Danish children, adolescents, and young adults.</p><p>In this population-based study, we used individual-level data from the Danish National Prescription Registry<span><sup>3</sup></span> to identify all individuals aged 5–24 years who filled a prescription for psychotropic medication from January 1, 2015, to December 31, 2023. Prescriptions for the following psychotropic drug classes were included: antipsychotics (Anatomical Therapeutic Chemical [ATC] code N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), antidepressants (N06A), and psychostimulants (N06B). For each month of the study period, we determined the number of incident users of each drug class and obtained the total number of 5–24-year-olds living in Denmark from the Danish Civil Registration System. Drug use was considered incident if there had been no prescription fill for the given drug in the previous 5 years.</p><p>Interrupted time series analysis was used to determine the monthly number of incident users of psychotropic medication in the post-pandemic period compared with the counterfactual pre-pandemic trend. Time-trends were modeled using Poisson regression with 105 data points. The model included three time segments: the pre-pandemic period (January 2015 to February 2020), the pandemic period (March 2020 to January 2022), and the post-pandemic period (from February 2022 until end of data availability). The end of the pandemic period was defined as January 2022, following the lifting of all Danish Covid-19-related restrictions. We modeled both the level and slope changes associated with each time segment and included Fourier terms and a scale parameter to account for seasonality and overdispersion (see Supplementary Methods).<span><sup>4</sup></span> Using model predictions, we obtained the cumulative number of incident psychotropic drug users in the post-pandemic period compared with pre-pandemic predictions and estimated the number of excess cases of incident psychotropic use and corresponding risk ratios (RR) with 95% confidence intervals (CI). The analysis was repeated for each psychotropic drug class and stratified by sex and age groups (5–11, 12–17, 18–24 years).</p><p>From 2015 through 2023, 182,097 Danish individuals aged 5–24 years filled an incident prescription for a psychotropic medication (55% female, median age 18.8 years [interquartile range 14.7–22.0]). The yearly incidence rate (IR) of psychotropic medication use increased from 1166 new users per 100,000 person-years (PY) in 2015
在 Covid-19 大流行期间,儿童、青少年和年轻人的心理健康状况恶化,导致精神药物的使用量同时大幅上升。在这项基于人群的研究中,我们使用了丹麦国家处方登记处3 的个人数据,以识别所有在 2015 年 1 月 1 日至 2023 年 12 月 31 日期间开过精神药物处方的 5-24 岁人群。处方包括以下精神药物类别:抗精神病药(解剖学治疗化学[ATC]代码 N05A)、抗焦虑药(N05B)、催眠药和镇静剂(N05C)、抗抑郁药(N06A)和精神兴奋剂(N06B)。在研究期间的每个月,我们确定了每类药物的偶发使用者人数,并从丹麦民事登记系统中获得了居住在丹麦的 5-24 岁人口总数。我们采用间断时间序列分析法来确定疫情流行后每月精神药物偶发使用者人数与疫情流行前趋势的对比情况。时间趋势模型采用泊松回归法,共有 105 个数据点。模型包括三个时间段:大流行前时期(2015 年 1 月至 2020 年 2 月)、大流行时期(2020 年 3 月至 2022 年 1 月)和大流行后时期(2022 年 2 月至数据可用性结束)。大流行期的结束被定义为 2022 年 1 月,即丹麦解除所有与 Covid-19 相关的限制之后。我们对与每个时间段相关的水平和斜率变化进行了建模,并加入了傅立叶项和一个规模参数,以考虑季节性和过度分散性(见补充方法)。4 通过模型预测,我们得出了疫情后时期与疫情前预测相比的精神药物使用者累计人数,并估算出了精神药物使用疫情的超额病例数和相应的风险比 (RR) 以及 95% 的置信区间 (CI)。从 2015 年到 2023 年,182,097 名 5-24 岁的丹麦人开具了精神药物处方(55% 为女性,中位年龄为 18.8 岁[四分位距为 14.7-22.0] )。精神药物使用的年发病率(IR)从 2015 年的每 10 万人年新增 1166 人增至 2023 年的每 10 万人年新增 2090 人(图 1)。这主要是由于精神刺激剂和催眠药的使用从 321 人/100,000 人年增加到 1007 人/100,000 人年,以及从 545 人/100,000 人年增加到 1251 人/100,000 人年。与疫情流行前的预测相比,疫情流行后的精神药物使用人数增加了 13,620 人(95% CI;9158-18,081),RR 为 1.36(1.20-1.51)。在大流行后时期,催眠药和精神兴奋剂的使用趋势继续增加,催眠药的使用人数增加了 11334 人(8535-14133 人),RR 为 1.59(1.37-1.80),精神兴奋剂的使用人数增加了 8409 人(6246-10572 人),RR 为 1.56(1.35-1.78)。抗抑郁药的使用也有所增加,超额使用人数为 4332 人(2222-6442),RR 为 1.24(1.10-1.38)。与预期趋势相比,抗精神病药或抗焦虑药的使用没有增加。与疫情流行前的预测相比,疫情流行后女性使用催眠药的RR为1.84(1.58-2.10),男性为1.33(1.14-1.52)。此外,女性使用精神刺激剂和抗抑郁剂的事件发生率分别为 2.24(1.87-2.60)和 1.37(1.20-1.53),而男性的相应发生率分别为 1.17(1.01-1.33)和 1.04(0.92-0.16)。所有年龄组的任何精神药物的新用药率在大流行后都有所上升。催眠药的情况也是如此,在所有年龄组中,新用药率都超过了大流行前的趋势,5-11 岁的新用药率为 1.33(1.08-1.57),12-17 岁的新用药率为 1.74(1.46-2.02),18-24 岁的新用药率为 1.60(1.38-1-81)。抗抑郁药的使用人数在所有年龄组中也较高(5-11 岁的 RR 为 1.60 [1.03-2.16],12-17 岁的 RR 为 1.70 [1.44-1.96],18-24 岁的 RR 为 1.16 [1.03-1.29])。然而,精神兴奋剂的使用只超过了对 12-17 岁和 18-24 岁青少年的预测,RR 分别为 1.76(1.50-2.01)和 1.92(1.61-2.23)。
{"title":"Post-pandemic trends in psychotropic medication use in Danish children, adolescents, and young adults","authors":"Helene Kildegaard,&nbsp;Rikke Wesselhoeft,&nbsp;Lars Christian Lund,&nbsp;Mette Bliddal","doi":"10.1111/acps.13719","DOIUrl":"10.1111/acps.13719","url":null,"abstract":"&lt;p&gt;Mental health among children, adolescents, and young adults deteriorated during the Covid-19 pandemic, leading to concurrent significant rises in utilization of psychotropics.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; This escalation in psychotropic medication use raised concerns for potential long-term effects beyond the immediate aftermaths of the pandemic. We aimed to assess rates of incident psychotropic medication use in the post-pandemic period compared with pre-pandemic trends in Danish children, adolescents, and young adults.&lt;/p&gt;&lt;p&gt;In this population-based study, we used individual-level data from the Danish National Prescription Registry&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; to identify all individuals aged 5–24 years who filled a prescription for psychotropic medication from January 1, 2015, to December 31, 2023. Prescriptions for the following psychotropic drug classes were included: antipsychotics (Anatomical Therapeutic Chemical [ATC] code N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), antidepressants (N06A), and psychostimulants (N06B). For each month of the study period, we determined the number of incident users of each drug class and obtained the total number of 5–24-year-olds living in Denmark from the Danish Civil Registration System. Drug use was considered incident if there had been no prescription fill for the given drug in the previous 5 years.&lt;/p&gt;&lt;p&gt;Interrupted time series analysis was used to determine the monthly number of incident users of psychotropic medication in the post-pandemic period compared with the counterfactual pre-pandemic trend. Time-trends were modeled using Poisson regression with 105 data points. The model included three time segments: the pre-pandemic period (January 2015 to February 2020), the pandemic period (March 2020 to January 2022), and the post-pandemic period (from February 2022 until end of data availability). The end of the pandemic period was defined as January 2022, following the lifting of all Danish Covid-19-related restrictions. We modeled both the level and slope changes associated with each time segment and included Fourier terms and a scale parameter to account for seasonality and overdispersion (see Supplementary Methods).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Using model predictions, we obtained the cumulative number of incident psychotropic drug users in the post-pandemic period compared with pre-pandemic predictions and estimated the number of excess cases of incident psychotropic use and corresponding risk ratios (RR) with 95% confidence intervals (CI). The analysis was repeated for each psychotropic drug class and stratified by sex and age groups (5–11, 12–17, 18–24 years).&lt;/p&gt;&lt;p&gt;From 2015 through 2023, 182,097 Danish individuals aged 5–24 years filled an incident prescription for a psychotropic medication (55% female, median age 18.8 years [interquartile range 14.7–22.0]). The yearly incidence rate (IR) of psychotropic medication use increased from 1166 new users per 100,000 person-years (PY) in 2015 ","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 3","pages":"174-177"},"PeriodicalIF":5.3,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13719","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141329772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the role of clinical and demographic characteristics on the effects of virtual reality cognitive behavioral therapy for psychosis: A moderator analysis. 探索临床和人口特征对虚拟现实认知行为疗法治疗精神病效果的影响:调节分析
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-09 DOI: 10.1111/acps.13713
M Berkhof, E C D van der Stouwe, R M C A Pot-Kolder, M van der Gaag, W Veling, C N W Geraets

Background: Virtual Reality cognitive behavioral therapy (VR-CBT) has proven to be an effective treatment method for paranoia and anxiety in psychosis. However, it is unknown, which individuals benefit most from VR-CBT. Previous studies examined factors affecting the treatment effect of regular CBTp, including illness duration, paranoia, depression, and pre-therapy avoidance behaviors, but results are inconsistent. The study aims to investigate the factors that influence the effectiveness of VR-CBT.

Methods: A total of 95 participants with a psychotic disorder and at least moderate paranoia (GTPS >40) were included in this explorative study. Data were collected as part of a multicenter randomized controlled trial in which participants were assigned to VR-CBT or treatment as usual (TAU). The VR-CBT group received 16 sessions of individual treatment. A moderator analysis was conducted to examine the influence of baseline demographic (age, gender, and education level) and clinical characteristics (duration of illness, paranoia, anxiety, depression, safety behavior, self-esteem, and social functioning) on treatment effects of paranoia and anxiety as measured with questionnaires and the experience sampling method (ESM) directly after treatment (12 weeks after baseline).

Results: More use of safety behavior at baseline resulted in greater benefits of VR-CBT on paranoid ideation and ESM paranoia. A higher age was associated with greater benefits of VR-CBT on social anxiety but not paranoia outcomes. There was no consistent evidence of moderation by any of the other sociodemographic or clinical variables for paranoid ideation and social anxiety.

Conclusions: Our findings suggest that a diverse spectrum of patients, with different backgrounds and symptom severity may be able to benefit from VR-CBT. VR-CBT can be recommended to a broad spectrum of patients with psychotic disorders, and particularly those with high levels of safety behaviors, including severe avoidance, seem to benefit more.

背景:虚拟现实认知行为疗法(VR-CBT虚拟现实认知行为疗法(VR-CBT)已被证明是治疗精神病患者妄想症和焦虑症的有效方法。然而,哪些人从虚拟现实认知行为疗法中获益最多,目前尚不清楚。之前的研究考察了影响常规 CBTp 治疗效果的因素,包括病程、妄想症、抑郁和治疗前的回避行为,但结果并不一致。本研究旨在调查影响 VR-CBT 效果的因素:本探索性研究共纳入了 95 名患有精神障碍且至少患有中度妄想症(GTPS >40)的参与者。数据收集是一项多中心随机对照试验的一部分,参与者被分配到 VR-CBT 或常规治疗(TAU)组。VR-CBT 组接受了 16 次个别治疗。研究人员对基线人口统计学特征(年龄、性别和教育水平)和临床特征(病程、偏执、焦虑、抑郁、安全行为、自尊和社会功能)进行了调节因子分析,以研究治疗后(基线12周后)直接使用调查问卷和经验取样法(ESM)测量的偏执和焦虑对治疗效果的影响:结果:基线时更多地使用安全行为会使 VR-CBT 对妄想症和 ESM 偏执症产生更大的益处。年龄越大,VR-CBT 对社交焦虑的疗效越大,但对妄想症的疗效不大。没有一致的证据表明其他社会人口学或临床变量对妄想症和社交焦虑有调节作用:我们的研究结果表明,不同背景和症状严重程度的患者都可能从 VR-CBT 中受益。VR-CBT可推荐给广泛的精神障碍患者,尤其是那些具有高度安全行为(包括严重回避)的患者,似乎更容易从中受益。
{"title":"Exploring the role of clinical and demographic characteristics on the effects of virtual reality cognitive behavioral therapy for psychosis: A moderator analysis.","authors":"M Berkhof, E C D van der Stouwe, R M C A Pot-Kolder, M van der Gaag, W Veling, C N W Geraets","doi":"10.1111/acps.13713","DOIUrl":"https://doi.org/10.1111/acps.13713","url":null,"abstract":"<p><strong>Background: </strong>Virtual Reality cognitive behavioral therapy (VR-CBT) has proven to be an effective treatment method for paranoia and anxiety in psychosis. However, it is unknown, which individuals benefit most from VR-CBT. Previous studies examined factors affecting the treatment effect of regular CBTp, including illness duration, paranoia, depression, and pre-therapy avoidance behaviors, but results are inconsistent. The study aims to investigate the factors that influence the effectiveness of VR-CBT.</p><p><strong>Methods: </strong>A total of 95 participants with a psychotic disorder and at least moderate paranoia (GTPS >40) were included in this explorative study. Data were collected as part of a multicenter randomized controlled trial in which participants were assigned to VR-CBT or treatment as usual (TAU). The VR-CBT group received 16 sessions of individual treatment. A moderator analysis was conducted to examine the influence of baseline demographic (age, gender, and education level) and clinical characteristics (duration of illness, paranoia, anxiety, depression, safety behavior, self-esteem, and social functioning) on treatment effects of paranoia and anxiety as measured with questionnaires and the experience sampling method (ESM) directly after treatment (12 weeks after baseline).</p><p><strong>Results: </strong>More use of safety behavior at baseline resulted in greater benefits of VR-CBT on paranoid ideation and ESM paranoia. A higher age was associated with greater benefits of VR-CBT on social anxiety but not paranoia outcomes. There was no consistent evidence of moderation by any of the other sociodemographic or clinical variables for paranoid ideation and social anxiety.</p><p><strong>Conclusions: </strong>Our findings suggest that a diverse spectrum of patients, with different backgrounds and symptom severity may be able to benefit from VR-CBT. VR-CBT can be recommended to a broad spectrum of patients with psychotic disorders, and particularly those with high levels of safety behaviors, including severe avoidance, seem to benefit more.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular mortality in bipolar disorder: Population-based cohort study 双相情感障碍的心血管死亡率:基于人群的队列研究。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-03 DOI: 10.1111/acps.13715
Tapio Paljärvi, Kimmo Herttua, Heidi Taipale, Markku Lähteenvuo, Antti Tanskanen, Jari Tiihonen

Background

Limited evidence base on cause-specific excess cardiovascular disease (CVD) mortality in bipolar disorder (BD) is a barrier to developing preventive interventions aimed at reducing the persistent mortality gap in BD.

Objective

To investigate cause-specific CVD mortality in BD.

Methods

We identified all individuals aged 15+ years during 2004–2018 with a diagnosis of BD using Finnish nationwide routine data. Standardised mortality ratios (SMR) with 95% confidence intervals (CI) were calculated using the mortality rates in the general population as weights.

Results

53,273 individuals with BD (57% women; median age at BD diagnosis, 40 years), were followed up for 428,426 person-years (median, 8.2 years). There were 5988 deaths due to any cause, of which 26% were due to CVD. The leading cause of absolute excess CVD mortality was coronary artery disease (CAD). The leading causes of relative excess mortality were cardiomegaly (SMR, 4.51; 95% CI, 3.58–5.43), venous thromboembolism (3.03; 2.26–3.81), cardiomyopathy (2.46; 1.95–2.97), and hypertensive heart disease (2.12; 1.71–2.54). The leading causes of absolute CVD mortality showed markedly lower relative excess, including CAD (1.47; 1.34–1.61), ischaemic stroke (1.31; 1.06–1.54), and acute myocardial infarction (1.12; 0.98–1.25). Due to the higher relative excess mortality, structural and functional heart disorders contributed as much as atherosclerotic and ischaemic disorders to the absolute excess mortality.

Conclusions

Cardiomyopathy and hypertensive heart disease as the leading causes of relative excess mortality emphasise the contribution of structural and functional heart disorders to the overall excess mortality alongside coronary artery disease. Interventions targeted at these modifiable causes of death should be priorities in the prevention of premature excess CVD mortality in BD.

背景:有关双相情感障碍(BD)中心血管疾病(CVD)特异性超额死亡率的证据基础有限,这阻碍了旨在减少双相情感障碍中持续存在的死亡率差距的预防性干预措施的制定:调查双相情感障碍患者心血管疾病死亡率的具体原因:我们利用芬兰全国范围内的常规数据,对 2004-2018 年间所有年龄在 15 岁以上、诊断为 BD 的患者进行了识别。以普通人群的死亡率为权重,计算标准化死亡率(SMR)及95%置信区间(CI):对 53273 名 BD 患者(57% 为女性;BD 诊断年龄中位数为 40 岁)进行了 428426 人年(中位数为 8.2 年)的随访。共有5988人死于任何原因,其中26%死于心血管疾病。心血管疾病绝对超额死亡率的主要原因是冠状动脉疾病(CAD)。导致相对超额死亡率的主要原因是心肌肥大(SMR,4.51;95% CI,3.58-5.43)、静脉血栓栓塞(3.03;2.26-3.81)、心肌病(2.46;1.95-2.97)和高血压性心脏病(2.12;1.71-2.54)。心血管疾病绝对死亡率的主要原因显示出明显较低的相对超额死亡率,包括 CAD(1.47;1.34-1.61)、缺血性中风(1.31;1.06-1.54)和急性心肌梗死(1.12;0.98-1.25)。由于相对超额死亡率较高,结构性和功能性心脏疾病与动脉粥样硬化和缺血性疾病对绝对超额死亡率的影响一样大:结论:心肌病和高血压性心脏病是导致相对超额死亡率的主要原因,这强调了结构性和功能性心脏疾病与冠状动脉疾病对总体超额死亡率的贡献。针对这些可改变的死因的干预措施应成为预防BD过早超额心血管疾病死亡率的优先事项。
{"title":"Cardiovascular mortality in bipolar disorder: Population-based cohort study","authors":"Tapio Paljärvi,&nbsp;Kimmo Herttua,&nbsp;Heidi Taipale,&nbsp;Markku Lähteenvuo,&nbsp;Antti Tanskanen,&nbsp;Jari Tiihonen","doi":"10.1111/acps.13715","DOIUrl":"10.1111/acps.13715","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Limited evidence base on cause-specific excess cardiovascular disease (CVD) mortality in bipolar disorder (BD) is a barrier to developing preventive interventions aimed at reducing the persistent mortality gap in BD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate cause-specific CVD mortality in BD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We identified all individuals aged 15+ years during 2004–2018 with a diagnosis of BD using Finnish nationwide routine data. Standardised mortality ratios (SMR) with 95% confidence intervals (CI) were calculated using the mortality rates in the general population as weights.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>53,273 individuals with BD (57% women; median age at BD diagnosis, 40 years), were followed up for 428,426 person-years (median, 8.2 years). There were 5988 deaths due to any cause, of which 26% were due to CVD. The leading cause of absolute excess CVD mortality was coronary artery disease (CAD). The leading causes of relative excess mortality were cardiomegaly (SMR, 4.51; 95% CI, 3.58–5.43), venous thromboembolism (3.03; 2.26–3.81), cardiomyopathy (2.46; 1.95–2.97), and hypertensive heart disease (2.12; 1.71–2.54). The leading causes of absolute CVD mortality showed markedly lower relative excess, including CAD (1.47; 1.34–1.61), ischaemic stroke (1.31; 1.06–1.54), and acute myocardial infarction (1.12; 0.98–1.25). Due to the higher relative excess mortality, structural and functional heart disorders contributed as much as atherosclerotic and ischaemic disorders to the absolute excess mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cardiomyopathy and hypertensive heart disease as the leading causes of relative excess mortality emphasise the contribution of structural and functional heart disorders to the overall excess mortality alongside coronary artery disease. Interventions targeted at these modifiable causes of death should be priorities in the prevention of premature excess CVD mortality in BD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 2","pages":"56-64"},"PeriodicalIF":5.3,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effects of individualism versus collectivism on clozapine policy stringency 个人主义与集体主义对氯氮平政策严格性的影响。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-02 DOI: 10.1111/acps.13714
Alexander B. Cohn, Yvonne S. Yang
{"title":"The effects of individualism versus collectivism on clozapine policy stringency","authors":"Alexander B. Cohn,&nbsp;Yvonne S. Yang","doi":"10.1111/acps.13714","DOIUrl":"10.1111/acps.13714","url":null,"abstract":"","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 3","pages":"180-181"},"PeriodicalIF":5.3,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early specialised treatment for bipolar disorder: Long-term follow-up from the early intervention in affective disorders (EIA) randomised controlled trial 双相情感障碍的早期专业治疗:情感障碍早期干预(EIA)随机对照试验的长期随访。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-06-02 DOI: 10.1111/acps.13716
Klaus Munkholm, Lars Vedel Kessing

Background

It is unclear whether treatment early after onset in bipolar disorder may improve the long-term illness course. The early intervention in affective disorders (EIA) randomised controlled trial found that 2-years treatment in a specialised mood disorder clinic combining evidence-based pharmacological treatment with group psychoeducation improved clinical outcomes compared with standard treatment in patients with bipolar disorder discharged after their 1st, 2nd, or 3rd hospital admission. We aimed to assess the 16 years long-term outcomes after randomisation of the participants in the EIA trial.

Methods

Data were obtained by linking nation-wide Danish population-based registers. All 158 participants of the EIA trial (Trial Registration Number NCT00253071) were followed from time of randomisation (2005–2009) to end of study (31 December 2021). The primary outcome was risk of psychiatric readmission. Secondary outcomes were total admissions and costs, medication use, intentional self-harm or suicide attempt or suicide, and socio-economic measures.

Results

The absolute mean risk of psychiatric readmission was 49.3% in the intervention group and 59.8% in the control group, with no statistically significant difference between the groups (b = −0.10, 95% CI: −0.26 to 0.047, p = 0.18). Compared with the control group, patients in the intervention group had numerically fewer total admission days (mean (SD) 44 (77) versus 62 (109)), lower total cost of psychiatric hospital admissions and hospital-based outpatient visits (mean (SD) 22,001 (36793) euros versus 29,822 (52671) euros) and higher use of lithium and antipsychotics, but the differences were not statistically significant. Fewer patients in the intervention group had an event of intentional self-harm or suicide attempt or suicide during follow-up (OR 0.25, 95% CI: 0.15–0.40, p < 0.001) compared with the control group and more patients in the intervention group used antiepileptics (OR 2.21, 95% CI: 1.08–4.60, p = 0.031).

Conclusion

Analyses of very long-term outcomes of the EIA trial may potentially indicate a beneficial effect of the intervention at the long term but were likely underpowered to detect a more subtle effect and for most outcomes the differences between groups were not statistically significant.

背景:目前尚不清楚躁郁症患者发病后尽早接受治疗是否能改善长期病程。情感障碍早期干预(EIA)随机对照试验发现,与标准治疗相比,在第一次、第二次或第三次入院后出院的双相情感障碍患者在情绪障碍专科门诊接受为期两年的治疗,结合循证药物治疗和集体心理教育,可改善临床疗效。我们的目的是评估EIA试验参与者随机分组后16年的长期疗效:方法:我们通过丹麦全国范围内的人口登记册获取数据。我们对 EIA 试验(试验注册号 NCT00253071)的所有 158 名参与者进行了从随机分配(2005-2009 年)到研究结束(2021 年 12 月 31 日)的跟踪调查。主要结果是精神疾病再入院风险。次要结果为入院总人数和费用、药物使用情况、故意自残或自杀未遂或自杀以及社会经济指标:干预组的精神病再入院绝对平均风险为 49.3%,对照组为 59.8%,组间差异无统计学意义(b = -0.10,95% CI:-0.26 至 0.047,p = 0.18)。与对照组相比,干预组患者入院总天数较少(平均(标清)44(77)天对62(109)天),精神科住院和医院门诊总费用较低(平均(标清)22001(36793)欧元对29822(52671)欧元),锂和抗精神病药物的使用率较高,但差异无统计学意义。对 EIA 试验的长期结果进行分析,有可能表明干预措施具有长期的有益效果,但可能不足以检测出更微妙的效果,而且对于大多数结果而言,组间差异在统计学上并不显著。
{"title":"Early specialised treatment for bipolar disorder: Long-term follow-up from the early intervention in affective disorders (EIA) randomised controlled trial","authors":"Klaus Munkholm,&nbsp;Lars Vedel Kessing","doi":"10.1111/acps.13716","DOIUrl":"10.1111/acps.13716","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>It is unclear whether treatment early after onset in bipolar disorder may improve the long-term illness course. The early intervention in affective disorders (EIA) randomised controlled trial found that 2-years treatment in a specialised mood disorder clinic combining evidence-based pharmacological treatment with group psychoeducation improved clinical outcomes compared with standard treatment in patients with bipolar disorder discharged after their 1st, 2nd, or 3rd hospital admission. We aimed to assess the 16 years long-term outcomes after randomisation of the participants in the EIA trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were obtained by linking nation-wide Danish population-based registers. All 158 participants of the EIA trial (Trial Registration Number NCT00253071) were followed from time of randomisation (2005–2009) to end of study (31 December 2021). The primary outcome was risk of psychiatric readmission. Secondary outcomes were total admissions and costs, medication use, intentional self-harm or suicide attempt or suicide, and socio-economic measures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The absolute mean risk of psychiatric readmission was 49.3% in the intervention group and 59.8% in the control group, with no statistically significant difference between the groups (<i>b</i> = −0.10, 95% CI: −0.26 to 0.047, <i>p</i> = 0.18). Compared with the control group, patients in the intervention group had numerically fewer total admission days (mean (SD) 44 (77) versus 62 (109)), lower total cost of psychiatric hospital admissions and hospital-based outpatient visits (mean (SD) 22,001 (36793) euros versus 29,822 (52671) euros) and higher use of lithium and antipsychotics, but the differences were not statistically significant. Fewer patients in the intervention group had an event of intentional self-harm or suicide attempt or suicide during follow-up (OR 0.25, 95% CI: 0.15–0.40, <i>p</i> &lt; 0.001) compared with the control group and more patients in the intervention group used antiepileptics (OR 2.21, 95% CI: 1.08–4.60, <i>p</i> = 0.031).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Analyses of very long-term outcomes of the EIA trial may potentially indicate a beneficial effect of the intervention at the long term but were likely underpowered to detect a more subtle effect and for most outcomes the differences between groups were not statistically significant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 3","pages":"138-147"},"PeriodicalIF":5.3,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13716","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital phenotyping data and anomaly detection methods to assess changes in mood and anxiety symptoms across a transdiagnostic clinical sample. 通过数字表型数据和异常检测方法,评估跨诊断临床样本中情绪和焦虑症状的变化。
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-05-28 DOI: 10.1111/acps.13712
Asher Cohen, John Naslund, Erlend Lane, Anant Bhan, Abhijit Rozatkar, Urvakhsh Meherwan Mehta, Aditya Vaidyam, Andrew Jin Soo Byun, Ian Barnett, John Torous

Introduction: Clinical assessment of mood and anxiety change often relies on clinical assessment or self-reported scales. Using smartphone digital phenotyping data and resulting markers of behavior (e.g., sleep) to augment clinical symptom scores offers a scalable and potentially more valid method to understand changes in patients' state. This paper explores the potential of using a combination of active and passive sensors in the context of smartphone-based digital phenotyping to assess mood and anxiety changes in two distinct cohorts of patients to assess the preliminary reliability and validity of this digital phenotyping method.

Methods: Participants from two different cohorts, each n = 76, one with diagnoses of depression/anxiety and the other schizophrenia, utilized mindLAMP to collect active data (e.g., surveys on mood/anxiety), along with passive data consisting of smartphone digital phenotyping data (geolocation, accelerometer, and screen state) for at least 1 month. Using anomaly detection algorithms, we assessed if statistical anomalies in the combination of active and passive data could predict changes in mood/anxiety scores as measured via smartphone surveys.

Results: The anomaly detection model was reliably able to predict symptom change of 4 points or greater for depression as measured by the PHQ-9 and anxiety as measured for the GAD-8 for both patient populations, with an area under the ROC curve of 0.65 and 0.80 for each respectively. For both PHQ-9 and GAD-7, these AUCs were maintained when predicting significant symptom change at least 7 days in advance. Active data alone predicted around 52% and 75% of the symptom variability for the depression/anxiety and schizophrenia populations respectively.

Conclusion: These results indicate the feasibility of anomaly detection for predicting symptom change in transdiagnostic cohorts. These results across different patient groups, different countries, and different sites (India and the US) suggest anomaly detection of smartphone digital phenotyping data may offer a reliable and valid approach to predicting symptom change. Future work should emphasize prospective application of these statistical methods.

简介情绪和焦虑变化的临床评估通常依赖于临床评估或自我报告量表。使用智能手机数字表型数据和由此产生的行为标记(如睡眠)来增强临床症状评分,为了解患者状态的变化提供了一种可扩展且更有效的方法。本文探讨了在基于智能手机的数字表型中结合使用主动和被动传感器来评估两组不同患者的情绪和焦虑变化的潜力,以评估这种数字表型方法的初步可靠性和有效性:来自两个不同组群的参与者(每个组群的人数均为76人,其中一个组群被诊断为抑郁/焦虑,另一个组群被诊断为精神分裂症)利用mindLAMP收集主动数据(如情绪/焦虑调查)以及由智能手机数字表型数据(地理位置、加速计和屏幕状态)组成的被动数据,时间至少为1个月。利用异常检测算法,我们评估了主动数据和被动数据组合中的统计异常是否能预测智能手机调查所测得的情绪/焦虑分数的变化:异常检测模型能够可靠地预测两个患者群体中 PHQ-9 测量的抑郁和 GAD-8 测量的焦虑的症状变化达到或超过 4 分,两者的 ROC 曲线下面积分别为 0.65 和 0.80。对于 PHQ-9 和 GAD-7,在预测至少 7 天前的显著症状变化时,这些 AUC 值都能保持不变。在抑郁/焦虑和精神分裂症人群中,仅活性数据就分别预测了约 52% 和 75% 的症状变化:这些结果表明了异常检测在跨诊断队列中预测症状变化的可行性。这些横跨不同患者群体、不同国家和不同地点(印度和美国)的结果表明,智能手机数字表型数据的异常检测可能是预测症状变化的一种可靠有效的方法。未来的工作应强调这些统计方法的前瞻性应用。
{"title":"Digital phenotyping data and anomaly detection methods to assess changes in mood and anxiety symptoms across a transdiagnostic clinical sample.","authors":"Asher Cohen, John Naslund, Erlend Lane, Anant Bhan, Abhijit Rozatkar, Urvakhsh Meherwan Mehta, Aditya Vaidyam, Andrew Jin Soo Byun, Ian Barnett, John Torous","doi":"10.1111/acps.13712","DOIUrl":"https://doi.org/10.1111/acps.13712","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical assessment of mood and anxiety change often relies on clinical assessment or self-reported scales. Using smartphone digital phenotyping data and resulting markers of behavior (e.g., sleep) to augment clinical symptom scores offers a scalable and potentially more valid method to understand changes in patients' state. This paper explores the potential of using a combination of active and passive sensors in the context of smartphone-based digital phenotyping to assess mood and anxiety changes in two distinct cohorts of patients to assess the preliminary reliability and validity of this digital phenotyping method.</p><p><strong>Methods: </strong>Participants from two different cohorts, each n = 76, one with diagnoses of depression/anxiety and the other schizophrenia, utilized mindLAMP to collect active data (e.g., surveys on mood/anxiety), along with passive data consisting of smartphone digital phenotyping data (geolocation, accelerometer, and screen state) for at least 1 month. Using anomaly detection algorithms, we assessed if statistical anomalies in the combination of active and passive data could predict changes in mood/anxiety scores as measured via smartphone surveys.</p><p><strong>Results: </strong>The anomaly detection model was reliably able to predict symptom change of 4 points or greater for depression as measured by the PHQ-9 and anxiety as measured for the GAD-8 for both patient populations, with an area under the ROC curve of 0.65 and 0.80 for each respectively. For both PHQ-9 and GAD-7, these AUCs were maintained when predicting significant symptom change at least 7 days in advance. Active data alone predicted around 52% and 75% of the symptom variability for the depression/anxiety and schizophrenia populations respectively.</p><p><strong>Conclusion: </strong>These results indicate the feasibility of anomaly detection for predicting symptom change in transdiagnostic cohorts. These results across different patient groups, different countries, and different sites (India and the US) suggest anomaly detection of smartphone digital phenotyping data may offer a reliable and valid approach to predicting symptom change. Future work should emphasize prospective application of these statistical methods.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Psychiatrica Scandinavica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1